0001493152-23-040030.txt : 20231109 0001493152-23-040030.hdr.sgml : 20231109 20231109152010 ACCESSION NUMBER: 0001493152-23-040030 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 EFFECTIVENESS DATE: 20231109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Voltron Therapeutics, Inc. CENTRAL INDEX KEY: 0001835742 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-464374 FILM NUMBER: 231391949 BUSINESS ADDRESS: STREET 1: 575 FIFTH AVE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: (212) 953-4936 MAIL ADDRESS: STREET 1: 575 FIFTH AVE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 D/A 1 primary_doc.xml X0708 D/A LIVE 0001835742 Voltron Therapeutics, Inc. 12 E 49TH STREET 11TH FLOOR NEW YORK NY NEW YORK 10017 646-335-5923 DELAWARE None None Corporation true Patrick Gallagher 12 E 49th Street 11th Floor New York NY NEW YORK 10017 Executive Officer Director Chief Executive Officer Matthew Duffy 12 E 49th Street 11th Floor New York NY NEW YORK 10017 Executive Officer Director President James Ahern 12 E 49th Street 11th Floor New York NY NEW YORK 10017 Director Paul Korner 12 E 49th Street 11th Floor New York NY NEW YORK 10017 Director Anthony Zook 12 E 49th Street 11th Floor New York NY NEW YORK 10017 Director Matthew Eitner 12 E 49th Street 11th Floor New York NY NEW YORK 10017 Director Biotechnology Decline to Disclose 06b true 0001493152-22-031074 2022-10-28 true true true true false 0 Laidlaw & Company (UK) Ltd. 119037 None None 521 FIFTH AVENUE, 12TH FLOOR NEW YORK NY NEW YORK 10175 AL ALABAMA CA CALIFORNIA CO COLORADO FL FLORIDA GA GEORGIA IL ILLINOIS IN INDIANA MA MASSACHUSETTS MI MICHIGAN MN MINNESOTA MO MISSOURI MT MONTANA NE NEBRASKA NH NEW HAMPSHIRE NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA OH OHIO PA PENNSYLVANIA SC SOUTH CAROLINA TX TEXAS WI WISCONSIN true Indefinite 3210680 Indefinite false 63 385282 true 0 0 false Voltron Therapeutics, Inc. /s/ Matthew Duffy Matthew Duffy President 2023-11-09